BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 28532709)

  • 1. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
    Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated prognosis of renal function decline in ADPKD patients using deep learning.
    Raj A; Tollens F; Caroli A; Nörenberg D; Zöllner FG
    Z Med Phys; 2024 May; 34(2):330-342. PubMed ID: 37612178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
    Bhutani H; Smith V; Rahbari-Oskoui F; Mittal A; Grantham JJ; Torres VE; Mrug M; Bae KT; Wu Z; Ge Y; Landslittel D; Gibbs P; O'Neill WC; Chapman AB;
    Kidney Int; 2015 Jul; 88(1):146-51. PubMed ID: 25830764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
    Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
    J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney volume and function in autosomal dominant polycystic kidney disease.
    Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
    Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.
    Kline TL; Korfiatis P; Edwards ME; Warner JD; Irazabal MV; King BF; Torres VE; Erickson BJ
    Nephrol Dial Transplant; 2016 Feb; 31(2):241-8. PubMed ID: 26330562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
    Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Srivastava A; Irazabal MV; Abebe KZ; Harris PC; Landsittel DP;
    J Am Soc Nephrol; 2020 Jul; 31(7):1640-1651. PubMed ID: 32487558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
    Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
    Bais T; Geertsema P; Knol MGE; van Gastel MDA; de Haas RJ; Meijer E; Gansevoort RT;
    Clin J Am Soc Nephrol; 2024 May; 19(5):591-601. PubMed ID: 38407866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.